1. Scrip
  2. >>R&D

Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail

Otsuka Obtains Global Rights To Two Drugs

 
• By Lisa Takagi

Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.

Sumitomo decided to prioritize other candidates than the four in the Otsuka deal amid financial challenges.
Sumitomo has decided to prioritize other R&D candidates over the four in its Otsuka alliance amid financial challenges • Source: Shutterstock

Amid recent financial challenges and R&D setbacks hitting Sumitomo Pharma Co., Ltd., the mid-sized Japanese firm has decided to prioritize its advanced candidates in oncology, regenerative medicine and the cell therapy area over its struggling assets in the antipsychotic space.

Sumitomo’s US subsidiary Sumitomo Pharma America, Inc. (SPMA) and Otsuka Pharmaceutical Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.